Establishment of Scientific Advisory Board

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience establishes Scientific Advisory Board

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces establishment of a scientific advisory board to support its medicines reformulation programme.

The Scientific Advisory Board shall consist of the Chief Technology Officer and independent world class experts, providing a broad range of expertise in both basic and clinical sciences, as well as technologies. The Scientific Advisory Board will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the Company's business.

As a first step, the company is appointing Professor Bill Dawson to serve on the scientific advisory board. Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes. Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D programmes is invaluable as we enter a new stage as a company. We plan to continue building the Scientific Advisory Board with further appointments in the coming months."

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Technology Officer +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 74963000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

About UCL (University College London)

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 24,000 students from almost 140 countries, and more than 9,500 employees. Our annual income is over £800 million.

www.ucl.ac.uk